Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.

The investigation concluded that by adding Hyasis®, the Bacillus-derived Hyaluronic Acid (HA) used in the study formulated by Novozymes Biopharma, into a tablet containing tramadol hydrochloride for oral administration, the release of tramadol hydrochloride can be prolonged from 1.9 to 7.5 hours. A good correlation has been identified between the added amounts of HA and the drug release time, and this correlation gives excellent possibilities for developing specific drug release profiles for different oral drug applications.

“These results represent another step forward in meeting the emerging challenges in drug development, and we are delighted to be presenting our latest findings at the CRS annual meeting,” says Hans Ole Klingenberg, Global Marketing Director, Novozymes Biopharma. “We are committed to developing compliant formulation solutions that ensure improved stability, solubility and half-life of therapeutics and we are delighted to demonstrate how these innovative products can streamline the drug development process.”

Experimentally, the drug release was assessed by dissolution analysis using a closed loop system configuration (SOTAX CE7smart) and USP 4 dissolution method with 22.4mm dissolution cells. The tramadol was detected on-line with UV absorbance at 270nm.

Novozymes Biopharma’s Hyasis® is an ultra-pure material with exceptionally low amounts of nucleic acids, proteins, bacterial endotoxins and microbial contamination. With a reproducible molecular weight and narrow size distribution, it is well-tolerated, safe and biocompatible, allowing the sustained and controlled release of drugs in a HA concentration dependent manner.

For further information on Novozymes’ range of innovative drug delivery products or to request a copy of the scientific poster, please visit booth 416 at the 2013 CRS meeting or www.biopharma.novozymes.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Novozymes Biopharma. (2013, July 22). Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®. News-Medical. Retrieved on December 10, 2019 from https://www.news-medical.net/news/20130722/Drug-release-of-tramadol-hydrochloride-increases-from-19-to-75-hours-by-adding-Novozymes-Biopharmae28099s-Hyasisc2ae.aspx.

  • MLA

    Novozymes Biopharma. "Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®". News-Medical. 10 December 2019. <https://www.news-medical.net/news/20130722/Drug-release-of-tramadol-hydrochloride-increases-from-19-to-75-hours-by-adding-Novozymes-Biopharmae28099s-Hyasisc2ae.aspx>.

  • Chicago

    Novozymes Biopharma. "Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®". News-Medical. https://www.news-medical.net/news/20130722/Drug-release-of-tramadol-hydrochloride-increases-from-19-to-75-hours-by-adding-Novozymes-Biopharmae28099s-Hyasisc2ae.aspx. (accessed December 10, 2019).

  • Harvard

    Novozymes Biopharma. 2013. Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®. News-Medical, viewed 10 December 2019, https://www.news-medical.net/news/20130722/Drug-release-of-tramadol-hydrochloride-increases-from-19-to-75-hours-by-adding-Novozymes-Biopharmae28099s-Hyasisc2ae.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Bruker launches BioPharmaCompass 1.1 software